C19orf57

Across TCGA pan-cancer cohorts, C19orf57 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of C19orf57’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where C19orf57 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types C19orf57 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

LIHC, LUAD, and THCA are the cancer types where C19orf57 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C19orf57 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.813	<.001	9	view →
LUAD	Female	All	+0.547	<.001	8	view →
THCA	Female	All	+0.305	<.001	8	view →
LUSC	Female	All	+1.335	<.001	7	view →
KIRC	Male	All	+0.198	<.001	5	view →
UCEC	All	All	+0.710	.003	4	view →
KIRP	All	II,III,IV	+0.674	.006	4	view →
STAD	All	All	+0.508	.005	4	view →
CHOL	All	All	+0.867	.001	2	view →
PRAD	All	All	−0.334	<.001	2	view →
READ	Female	All	+1.028	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

C19orf57–LIHC

Open the LIHC breakdown →